FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103402364> ?p ?o ?g. }

• W2103402364 endingPage "503" @default.
• W2103402364 startingPage "493" @default.
• W2103402364 abstract "Abstract Objective To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are critical in disease pathogenesis. Methods Lupus‐prone mice were treated with the nonselective proteasome inhibitors carfilzomib and bortezomib, the immunoproteasome inhibitor ONX 0914, or vehicle control. Tissue was harvested and analyzed by flow cytometry using standard markers. Nephritis was monitored by evaluation for proteinuria and by histologic analysis of kidneys. Serum anti–double‐stranded DNA (anti‐dsDNA) levels were measured by enzyme‐linked immunosorbent assay (ELISA), and total IgG and dsDNA antibody‐secreting cells (ASCs) by enzyme‐linked immunospot assay. Human peripheral blood mononuclear cells or mouse bone marrow cells were incubated with Toll‐like receptor (TLR) agonists and proteasome inhibitors, and interferon‐α (IFNα) levels were measured by ELISA and flow cytometry. Results Early treatment of lupus‐prone mice with the dual‐targeting proteasome inhibitors carfilzomib or bortezomib or the immunoproteasome‐specific inhibitor ONX 0914 prevented disease progression, and treatment of mice with established disease dramatically abrogated nephritis. Treatment had profound effects on plasma cells, with greater reductions in autoreactive than in total IgG ASCs, an effect that became more pronounced with prolonged treatment and was reflected in decreasing serum autoantibody levels. Notably, proteasome inhibition efficiently suppressed production of IFNα by TLR‐activated PDCs in vitro and in vivo, an effect mediated by inhibition of both PDC survival and PDC function. Conclusion Inhibition of the immunoproteasome is equally efficacious as dual targeting agents in preventing lupus disease progression by targeting 2 critical pathways in disease pathogenesis, type I IFN activation and autoantibody production by plasma cells." @default.
• W2103402364 created "2016-06-24" @default.
• W2103402364 creator A5002780483 @default.
• W2103402364 creator A5008089732 @default.
• W2103402364 creator A5009941227 @default.
• W2103402364 creator A5014590160 @default.
• W2103402364 creator A5025740932 @default.
• W2103402364 creator A5031145721 @default.
• W2103402364 creator A5045439691 @default.
• W2103402364 creator A5047455011 @default.
• W2103402364 creator A5051553294 @default.
• W2103402364 creator A5064361774 @default.
• W2103402364 creator A5071236331 @default.
• W2103402364 creator A5071531582 @default.
• W2103402364 date "2012-01-27" @default.
• W2103402364 modified "2023-10-16" @default.
• W2103402364 title "Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells" @default.
• W2103402364 cites W1547552531 @default.
• W2103402364 cites W1672219033 @default.
• W2103402364 cites W1733031769 @default.
• W2103402364 cites W1924968745 @default.
• W2103402364 cites W1965672602 @default.
• W2103402364 cites W1974010669 @default.
• W2103402364 cites W1978231377 @default.
• W2103402364 cites W1984815506 @default.
• W2103402364 cites W1993290536 @default.
• W2103402364 cites W2005284010 @default.
• W2103402364 cites W2007442168 @default.
• W2103402364 cites W2010675961 @default.
• W2103402364 cites W2016742872 @default.
• W2103402364 cites W2020437934 @default.
• W2103402364 cites W2027632198 @default.
• W2103402364 cites W2036139631 @default.
• W2103402364 cites W2046330020 @default.
• W2103402364 cites W2047650149 @default.
• W2103402364 cites W2056390097 @default.
• W2103402364 cites W2067653691 @default.
• W2103402364 cites W2068547289 @default.
• W2103402364 cites W2072714194 @default.
• W2103402364 cites W2074051660 @default.
• W2103402364 cites W2074871929 @default.
• W2103402364 cites W2077221873 @default.
• W2103402364 cites W2077570217 @default.
• W2103402364 cites W2084928543 @default.
• W2103402364 cites W2089016290 @default.
• W2103402364 cites W2106273198 @default.
• W2103402364 cites W2106566281 @default.
• W2103402364 cites W2107927044 @default.
• W2103402364 cites W2111732928 @default.
• W2103402364 cites W2114204948 @default.
• W2103402364 cites W2126267349 @default.
• W2103402364 cites W2136394997 @default.
• W2103402364 cites W2141812411 @default.
• W2103402364 cites W2149168654 @default.
• W2103402364 cites W2160025824 @default.
• W2103402364 cites W2164706843 @default.
• W2103402364 cites W2166635088 @default.
• W2103402364 cites W2166761147 @default.
• W2103402364 cites W2168888135 @default.
• W2103402364 cites W2318971911 @default.
• W2103402364 cites W2992496655 @default.
• W2103402364 doi "https://doi.org/10.1002/art.33333" @default.
• W2103402364 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4584406" @default.
• W2103402364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21905015" @default.
• W2103402364 hasPublicationYear "2012" @default.
• W2103402364 type Work @default.
• W2103402364 sameAs 2103402364 @default.
• W2103402364 citedByCount "213" @default.
• W2103402364 countsByYear W21034023642012 @default.
• W2103402364 countsByYear W21034023642013 @default.
• W2103402364 countsByYear W21034023642014 @default.
• W2103402364 countsByYear W21034023642015 @default.
• W2103402364 countsByYear W21034023642016 @default.
• W2103402364 countsByYear W21034023642017 @default.
• W2103402364 countsByYear W21034023642018 @default.
• W2103402364 countsByYear W21034023642019 @default.
• W2103402364 countsByYear W21034023642020 @default.
• W2103402364 countsByYear W21034023642021 @default.
• W2103402364 countsByYear W21034023642022 @default.
• W2103402364 countsByYear W21034023642023 @default.
• W2103402364 crossrefType "journal-article" @default.
• W2103402364 hasAuthorship W2103402364A5002780483 @default.
• W2103402364 hasAuthorship W2103402364A5008089732 @default.
• W2103402364 hasAuthorship W2103402364A5009941227 @default.
• W2103402364 hasAuthorship W2103402364A5014590160 @default.
• W2103402364 hasAuthorship W2103402364A5025740932 @default.
• W2103402364 hasAuthorship W2103402364A5031145721 @default.
• W2103402364 hasAuthorship W2103402364A5045439691 @default.
• W2103402364 hasAuthorship W2103402364A5047455011 @default.
• W2103402364 hasAuthorship W2103402364A5051553294 @default.
• W2103402364 hasAuthorship W2103402364A5064361774 @default.
• W2103402364 hasAuthorship W2103402364A5071236331 @default.
• W2103402364 hasAuthorship W2103402364A5071531582 @default.
• W2103402364 hasBestOaLocation W21034023641 @default.
• W2103402364 hasConcept C126322002 @default.
• W2103402364 hasConcept C137061746 @default.
• W2103402364 hasConcept C150903083 @default.
• W2103402364 hasConcept C159654299 @default.

• next